TPO-RA Treatment on Immune Tolerance Induction of ITP Patients With Sustained Platelet Recovery After Treatment Termination

NCT06478537 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

56

Enrollment

OTHER

Sponsor class

Conditions

Immune Thrombocytopenia

Interventions

DRUG: Hetrombopag Olamine
DRUG: Aspirin

Sponsor

Peking Union Medical College Hospital